Eclipse Regenesis

medical devices

About

The first tissue regeneration therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. It results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. The Eclipse XL1 therapy is designed to grow 2-3x longer, healthy intestine within 2-3 weeks using an entirely mechanical, repeatable approach. The new tissue has been shown to absorb nutrients and function the same as, or better than, healthy intestinal tissue. The Eclipse XL 1 device is an investigational product and limited by Federal law to investigational use. It is not currently available for commercial sale in the U.S. or any other region. Eclipse Regenesis and Eclipse XL1 are registered trademarks of Eclipse Regenesis, Inc.

Technologies

Gmail Google Apps Microsoft Office 365 Typekit Google Tag Manager WordPress.org Mobile Friendly Apache YouTube Remote Android

Keywords

short bowel syndrome medical device tissue regeneration therapy medical equipment and supplies manufacturing surgical innovation collaborative healthcare partnerships intestinal lengthening pediatric gastrointestinal therapy biotechnology clinical trials growth of functional intestinal tissue intestinal tissue growth in vivo b2b clinical development mechanical device biomechanical force technology intestinal failure treatment device development patient-centered innovation spring device for sbs gastrointestinal tissue engineering tissue regeneration peer-reviewed publications biomechanical force application regenerative therapy technology non-invasive tissue expansion intestinal health intestinal tissue growth intestinal tissue regeneration intestinal tissue engineering in pediatrics

Location

1440 O'Brien Dr, Menlo Park, California, United States, 94025-1432

Related Companies

Companies in the same industry